• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Meningococcal Vaccine
    4 Drugs classified under this drug class


    All the Drug Class Drugs

    Bexsero
    GSK
    RX
    not in the basket chart
    Bexsero

    Meningococcal Vaccine. Neisseria Meningitidis Vaccine 50 mcg / 0.5 ml.
    PRE-FILL. SYR. (susp. for inj.): 1,10×0.5ml. Interval of inject. accord. to instructs. of M.O.H. for IM inj.
    Active immuniz. of individuals from 2 mnths. of age and older against invas. meningococcal dis. caused by Neisseria meningitidis group B.
    C/I: Hypersens.

    Menactra®
    Medici
    RX
    partial basket chart
    Multiple ingredients
    Menactra®

    Meningococcal Vaccine, Toxoid Conjugate Vaccine. Meningococcal Serogroup A 0.4 mcg / 0.5 ml, Meningococcal Serogroup C 0.4 mcg / 0.5 ml, Meningococcal Serogroup Y 0.4 mcg / 0.5 ml, Meningococcal Serogroup W135 0.4 mcg / 0.5 ml.
    VIAL (Sol. for IM Inj.): 1,5×0.5 ml. Admin. as a 0.5 mL dose by IM inj.
    Do not admin. this product IV or S.C.
    Primary Vaccination: In child. 9 through 23 mnths. of age, the vaccine is given as a 2-dose series three mnths. apart.
    Individuals 2 through 55 yrs. of age- given as a single dose.
    Booster Vaccination: A single booster dose may be given to individuals 15 through 55 yrs. of age at continued risk for meningococc. dis., if at least 4 yrs. have elapsed since the prior dose.
    Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococ. dis. caused by Neisseria meningitidis serogroups A, C, Y and W-135. This vaccine is approved for use in individuals 9 mnths. through 55 yrs. of age and does not prevent N meningitides serogroup B dis.
    C/I: Sev. allergic react. (eg, anaphylaxis) after a previous dose of a mening. capsular polysaccharide, diphtheria toxoid- or CRM197-contain. vaccine.

    Nimenrix
    Pfizer
    RX
    partial basket chart
    Nimenrix

    Meningococcal Vaccine. Neisseria Meningitidis Vaccine 5 μg/0.5 ml.
    VIAL (pwdr. and solvent for sol. for IM inj.): 1, 10, 100 × single dose (0.5ml). Should be used in accordance with available official recommend.
    Primary immunisat.
    Infants from 6 wks. to less than 6 mnths. of age: two doses, each of 0.5 ml, should be admin. with an interval of 2 mnths. betwn. doses.
    Infants from 6 mnths. of age, child., adolesc. and adult.: a single 0.5 mL dose should be admin.
    An addit. primary dose of this vaccine may be consid. appropr. for some individuals.
    Booster doses: After complet. of the prim. immunisat. course in infants 6 wks. to less than 12 mnths. of age, a booster dose should be given at 12 mnths. of age with an interval of at least 2 mnths. after the last Nimenrix vaccinat.
    Indicated for active immunisat. of individuals from the age of 6 wks. against invas. meningococc. dis. caused by Neisseria meningitidis group A, C, W-135 and Y.
    C/I: Hypersens.

    CLOSE